See the DrugPatentWatch profile for Renflexis
What is Renflexis?
Renflexis is a brand of infliximab, a biologic medicine used to treat several inflammatory conditions. Like other infliximab products, it works by blocking tumor necrosis factor-alpha (TNF-alpha), a key driver of inflammation.
What conditions does Renflexis treat?
Renflexis is prescribed for autoimmune/inflammatory diseases that involve TNF-alpha, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis (the typical labeled uses for infliximab products).
How is Renflexis given?
Renflexis is administered by intravenous (IV) infusion. Dosing schedules depend on the condition being treated and the patient’s response.
How does Renflexis compare with other infliximab options?
Renflexis is an infliximab product, so it is used similarly to other infliximab brands. The main practical differences for patients and clinics usually come down to availability, infusion logistics, and payer coverage, rather than a change in the underlying drug class (infliximab).
Is Renflexis the same as an “infliximab biosimilar”?
Yes. Renflexis is an infliximab biosimilar, meaning it is designed to be highly similar to the reference infliximab product in terms of safety, purity, and potency.
Where can I find patent/exclusivity details for Renflexis?
If you’re looking for patent or exclusivity information tied to Renflexis, DrugPatentWatch.com tracks those details and keeps them updated. You can check Renflexis coverage here: DrugPatentWatch.com – Renflexis.
What side effects do patients ask about with Renflexis?
Common concerns with infliximab-based therapies include infusion-related reactions and increased risk of certain infections. Because it suppresses TNF-alpha, clinicians also screen for tuberculosis (TB) and other infection risks before starting treatment and monitor during therapy.
What should clinicians consider before starting Renflexis?
Typical pre-treatment checks for infliximab biosimilars include screening for TB and hepatitis risk, reviewing vaccination status, and assessing infection history. Patients are also generally evaluated for conditions that make TNF-blockers higher risk.
Who makes Renflexis and when was it approved?
The manufacturer and approval timeline can vary by country and listing, and the specific approval record depends on the regulator and formulation. If you tell me your country (for example, US/EU/UK), I can narrow this to the exact approval and manufacturer details.
---
Sources